Company / Total Debt
Myriad Genetics, Inc. Total Debt History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$119.9M
FY2025
5-year range
$0 / $119.9M
FY2021-FY2025
Trend
+202.8%
vs FY2024
Sector context
#52 of 83
Health Care
What the data says
Total Debt changed +203% YoY in FY2025, a notable deviation from the 6-year average annual change of +404%.
Based on SEC 10-K filings.
$120M in FY2025 with a 5-year CAGR of -11.8%.
Increased from $39M to $120M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -11.8%
- 10-Year CAGR
- -
Sector benchmark
#32 of 83 in Health CareTop 37% of 83This company $119.9M Sector average $6.2B
▼
-98.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -11.8%, indicating a declining trend.
- In FY2025, total debt increased 202.8% year-over-year.
- Ranks #52 out of 83 companies in the Health Care sector.
- Peak total debt was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $119.9M | +202.8% |
| FY2024 | $39.6M | +2.9% |
| FY2023 | $38.5M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $224.8M | -3.7% |
| FY2019 | $233.5M | +2410.8% |
| FY2018 | $9.3M | -90.6% |
| FY2017 | $99.1M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026